Pancreatic Cancer Research

ResearcherTranslational Genomics Research InstituteActive in the last 2 years

Daniel H. Palmer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5766-9990; OpenAlex author ID A5025272654. Sources: OpenAlex.

Their work

Papers
44 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
169
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 5 papers · 2017: 6 papers · 2018: 9 papers · 2019: 4 papers · 2020: 3 papers · 2021: 2 papers · 2022: 3 papers · 2023: 4 papers · 2024: 4 papers · 2025: 3 papers

Papers 44

  1. Cost-Effectiveness of Biomarker-Associated Early Pancreatic Cancer Detection in New-Onset Diabetes. Co-author DOI 10.1001/jamanetworkopen.2025.38031↗
  2. Reply to: Adjuvant Treatment Options and Modalities in Pancreatic Adenocarcinoma: Insights From ESPAC4. Co-author DOI 10.1200/jco-25-00333↗
  3. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  4. Macrophage-fibroblast JAK/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer. Co-author DOI 10.1038/s41467-024-47949-3↗
  5. Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis. Co-author DOI 10.1038/s43018-024-00731-2↗
  6. Author Correction: Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis. Co-author DOI 10.1038/s43018-024-00751-y↗
  7. Multicohort study testing the generalisability of the SASKit-ML stroke and PDAC prognostic model pipeline to other chronic diseases. Co-author DOI 10.1136/bmjopen-2024-088181↗
  8. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… First author DOI 10.1016/s2468-1253(22)00348-x↗
  9. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325803↗
  10. Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world stud… Co-author DOI 10.1186/s12885-023-11377-1↗
  11. The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100P Gene Expression in Cells and in an In Vivo Model of Pancreatic Cancer. Co-author DOI 10.3390/molecules28062452↗
  12. Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE) following initial systemic chemotherapy (LAP-… Co-author DOI 10.1136/bmjopen-2021-050166↗
  13. United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early de… Co-author DOI 10.1136/bmjopen-2022-068010↗
  14. Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. Co-author DOI 10.1136/gutjnl-2021-325272↗
  15. Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". Co-author DOI 10.1038/s41416-020-01133-8↗
  16. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
  17. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-020-0846-2↗
  18. Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. Co-author DOI 10.1038/s41416-020-0980-x↗
  19. Towards biomarkers for outcomes after pancreatic ductal adenocarcinoma and ischaemic stroke, with focus on (co)-morbidity and ageing/cellular senescence (SASKi… Co-author DOI 10.1136/bmjopen-2020-039560↗
  20. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Co-author DOI 10.1001/jamasurg.2019.3337↗
  21. Chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.lpm.2019.02.025↗
  22. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Co-author DOI 10.1016/j.pan.2018.10.003↗
  23. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002557↗
  24. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single… Last author DOI 10.1007/s40273-017-0592-3↗
  25. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Te… Last author DOI 10.1007/s40273-018-0646-1↗
  26. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2017.495↗
  27. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
  28. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
  29. Therapeutic developments in pancreatic cancer: current and future perspectives. Last author DOI 10.1038/s41575-018-0005-x↗
  30. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  31. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Tria… Co-author DOI 10.1097/sla.0000000000002088↗
  32. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-3876↗
  33. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2016.3916↗
  34. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based… Last author DOI 10.1002/bjs.10482↗
  35. Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer. Co-author DOI 10.1016/j.drudis.2017.01.012↗
  36. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-lab… First author DOI 10.1016/s0140-6736(16)32409-6↗
  37. Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre. Last author DOI 10.1038/bjc.2016.406↗
  38. Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer. Last author DOI 10.18632/oncotarget.18879↗
  39. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  40. Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2015.468↗
  41. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1038/bjc.2016.277↗
  42. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Co-author DOI 10.1038/ncb3340↗
  43. Corrigendum: Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Co-author DOI 10.1038/ncb3377↗
  44. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Co-author DOI 10.1093/jnci/djt347↗

Closest collaborators

The 25 strongest of 169 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paula Ghaneh · 23 shared papers, 2014–2025 · strength 2.21
  2. Christopher Michael Halloran · 18 shared papers, 2014–2025 · strength 1.88
  3. John P. Neoptolemos · 20 shared papers, 2014–2025 · strength 1.74
  4. William Greenhalf · 16 shared papers, 2014–2025 · strength 1.42
  5. Eithne Costello · 14 shared papers, 2014–2025 · strength 1.19
  6. Juan W. Valle · 13 shared papers, 2014–2025 · strength 1.03
  7. Thilo Hackert · 8 shared papers, 2017–2025 · strength 1.03
  8. Valeria Quaranta · 7 shared papers, 2016–2024 · strength 0.81
  9. Michael C. Schmid · 7 shared papers, 2016–2024 · strength 0.81
  10. Ainhoa Mielgo Iza · 7 shared papers, 2016–2024 · strength 0.81
  11. Markus Wolfgang Büchler · 12 shared papers, 2014–2023 · strength 0.79
  12. Meirion Raymant Raymant · 5 shared papers, 2018–2024 · strength 0.71
  13. Christoph Springfeld · 4 shared papers, 2019–2025 · strength 0.70
  14. Yuliana Astuti · 4 shared papers, 2022–2024 · strength 0.64
  15. Gaia Bellomo · 4 shared papers, 2022–2024 · strength 0.64
  16. Jennifer P. Morton · 4 shared papers, 2022–2024 · strength 0.64
  17. Robert Peter Jones · 5 shared papers, 2017–2024 · strength 0.59
  18. Bengt L. G. Glimelius · 8 shared papers, 2014–2025 · strength 0.57
  19. Alan Anthoney · 9 shared papers, 2014–2021 · strength 0.54
  20. Yuk Ting Ma · 6 shared papers, 2017–2025 · strength 0.54
  21. David Cunningham · 5 shared papers, 2017–2025 · strength 0.48
  22. Christoph W. Michalski · 2 shared papers, 2025 · strength 0.47
  23. Harpreet Singh Wasan · 5 shared papers, 2017–2025 · strength 0.46
  24. Julia V. Mayerle · 8 shared papers, 2014–2021 · strength 0.46
  25. Markus M. Lerch · 7 shared papers, 2016–2021 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.